The findings suggest that Bruton's tyrosine kinase inhibition may emerge as a promising therapeutic intervention in HS.
, from the Clinical Laboratory for Epidemiology and Applied Research in Skin at Beth Israel Deaconess Medical Center, Boston, said at the annual meeting of the American Academy of Dermatology. "However, several additional pathways are thought to contribute to disease pathogenesis."
There were slightly more women than men and more than 90% of study participants were White. The novel drug, which is being developed by Novartis, is also under investigation in other immune-mediated inflammatory diseases, including chronic spontaneous Kimball, who is also a professor of dermatology at Harvard University, reported that 80.2% of patients overall completed treatment: 87.9% and 78.8% in the remibrutinib 25 mg and 100 mg arms, respectively, and 76% in the pooled placebo arm. The main reason for treatment discontinuation was patient decision . Nearly three quarters of patients in the remibrutinib 25 mg twice-daily arm achieved the simplified HiSCR endpoint, compared with 48.
The researchers also observed a greater response on the Patient's Global Assessment of Skin Pain Numeric Rating Scale 30 in patients treated with remibrutinib compared with those on placebo at week 16 .
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New treatment for food allergies shows promiseThis is additional taxonomy that helps us with analytics
Read more »
Revolutionary Brain Stimulation Technique Shows Promise for Treating Neurological DisordersScience, Space and Technology News 2024
Read more »
Feds: Drug trafficker 'executed' 2 witnesses, including pregnant mother, in San Diego-based drug prosecutionsAuthorities allege Benjamin Madrigal-Birrueta and at least one co-conspirator murdered the two witnesses and buried them in a desert grave in central Washington state
Read more »
Researchers explore non-invasive method for sampling drug responseHarnessing a pervasive type of cellular messenger shows early experimental promise as a routine way of sampling and monitoring the body's response to prescription drug exposure.
Read more »
These Frame smart glasses promise ‘AI superpowers’ for $349Brilliant Labs is launching a pair of smart glasses, called Frame, which use multimodal AI to enable visual analysis, translation, web search, and more.
Read more »
Gene Therapy’s Promise Meets Nigeria’s Sickle Cell RealityThe U.S. FDA approved a breakthrough treatment for sickle cell anemia. But in Nigeria, social changes could make a bigger difference.
Read more »